Novo Nordisk, Roche Partner in Diabetes ProductBy
Novo Nordisk has launched NovoRapid PumpCart, a prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. This new treatment solution, which contains NovoRapid (insulin aspart), a rapid-acting insulin from Novo Nordisk, is expected to make insulin pump therapy more convenient for people with diabetes and their care staff. The 1.6-mL cartridge is developed in a non-exclusive partnership between Roche Diabetes Care and Novo Nordisk and is compatible with the new Accu-Chek Insight insulin pump therapy system from Roche Diabetes Care.
An insulin pump delivers insulin from a reservoir inside the pump to a patient’s body using an infusion set and a tiny cannula. Insulin pumps use fast-acting insulin, such as insulin aspart. The insulin is delivered using continuous infusion and is often used by people with type 1 diabetes who receive intensified insulin therapy and test their blood glucose levels on a regular basis. An insulin pump is suitable for certain patients and provides more flexibility, with the potential to improve glycaemic control.
NovoRapid PumpCart is being launched in the UK, Sweden, and Austria today and will be made available in more European countries throughout 2015 and 2016. The Accu-Chek Insight insulin pump therapy system was launched in Austria in the first half of this year and is currently being launched in the UK, with other European markets following throughout 2015.
Source: Novo Nordisk